{"id":53167,"date":"2023-01-23T12:02:33","date_gmt":"2023-01-23T11:02:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-hepatitis-c-testing-market-report-to-2031-players-include-abbott-laboratories-bio-rad-laboratories-cosara-diagnostics-and-illumina-researchandmarkets-com\/"},"modified":"2023-01-23T12:02:33","modified_gmt":"2023-01-23T11:02:33","slug":"global-hepatitis-c-testing-market-report-to-2031-players-include-abbott-laboratories-bio-rad-laboratories-cosara-diagnostics-and-illumina-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-hepatitis-c-testing-market-report-to-2031-players-include-abbott-laboratories-bio-rad-laboratories-cosara-diagnostics-and-illumina-researchandmarkets-com\/","title":{"rendered":"Global Hepatitis C Testing Market Report to 2031 – Players Include Abbott Laboratories, BIO-RAD Laboratories, Cosara Diagnostics and Illumina – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Hepatitis C Testing Market By Technique, By Test, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031.\n<\/p>\n

\nHepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C can be diagnosed with antibody test, genotype test, and viral load test.\n<\/p>\n

\nThe increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market. For instance, according to a report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have the chronic hepatitis C infection. Thus, increase in prevalence of hepatitis C globally boosts the growth of the market.\n<\/p>\n

\nIn addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis C virus transmission.\n<\/p>\n

\nFor instance, as per the report of World Health Organization (WHO) published on May 2022, about 118.54 million blood donations are made worldwide. 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis C, and syphilis should be mandatory.\n<\/p>\n

\nMoreover, increase in R&D activities for development of advanced hepatitis C testing such as immunoassay & polymerase chain reaction (PCR), rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth.\n<\/p>\n

\nKey Benefits For Stakeholders<\/strong>\n<\/p>\n